Mesothelioma, an aggressive and fatal cancer, continues to affect thousands of Americans, but veterans remain among the hardest affected. The main issue for affected veterans is that mesothelioma is ...

Cancer biotech Vivace Therapeutics is tuning up for a phase 3 trial after its potential first-in-class small molecule scored a 32% objective response rate in patients with treatment-resistant ...